Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Observational 2Interventional 1

Sponsor

Cancer Type

Breast 7Gastrointestinal 6Tumor-Agnostic 3Thoracic 2CNS 2Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1

Conditions

Neoplasms 3

Interventions

Surveys and Questionnaires 70Blood Specimen Collection 48Radiotherapy 39Magnetic Resonance Spectroscopy 35pembrolizumab 31Gemcitabine 30Bevacizumab 30Nivolumab 29Carboplatin 29Radiosurgery 27Standard of Care 26Oxaliplatin 26Capecitabine 25Paclitaxel 24Interviews as Topic 24Cisplatin 24Fluorouracil 23Erlotinib Hydrochloride 22Everolimus 19Irinotecan 18Trastuzumab 17Methods 17Exercise 17Docetaxel 17Biopsy 17Cyclophosphamide 16Educational Status 15Sorafenib 14Ipilimumab 14Fluorodeoxyglucose F18 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Acceptance and Commitment Therapy × Tumor-Agnostic × Clear all
NCT05126823 2026-05-05

Efficacy of a Combined ACT+ App Intervention to Improve Psychological Flexibility and Associated Symptoms in Cancer Patients

Universidad de Córdoba

Phase NA Active not recruiting
120 enrolled
Tumor-Agnostic

Neoplasms

NCT03910296 2022-05-03

Acceptance and Commitment Therapy (ACT) - Based Treatment Development for Cancer Patients Treated for Pain

Dana-Farber Cancer Institute

Completed
10 enrolled
Tumor-Agnostic

Neoplasms

NCT04636346 2020-12-17

COMPASS: A Group ACT Program for Cancer Patients Treated at UCSF

University of California, San Francisco

Completed
129 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡